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C O N T R O V E R S I A L Q U E S T I O N
What symptom should be 
the primary treatment target 
in depression?
patients’ two main complaints, namely anxiety
and sleep disturbance. However, the combination
of anxiolytics and hypnotics is invaluable for this
purpose. Depressed mood will lift at a later stage,
followed by the recovery of interest and pleasure.
Damaged brain needs time to recover. The more
complex the psychological function, the longer
it takes to improve. Even recovered depressives
remain psychologically different from healthy
controls, in terms of negativity and hesitation.
We still don’t know whether this represents the
residue of a depressive episode or a preexisting
personality trait that predisposes to depression.
Placebo can achieve improvements rates of up to
35% in depression. Since antidepressant efficacy
averages no more than 50%, the margin of phar-
macology over placebo is only 15%. Although
placebo may be able to relieve all symptoms of
depression, there is no evidence that it works bet-
ter on some symptoms rather than others. True
remission rates are much lower on placebo, by a
difference well in excess of 15%. In other words,
placebo may improve symptoms, but it tends not
to eradicate them. Placebo appears particularly
effective for somatoform symptoms that are often
hard to classify as psychological, cognitive, or
physical. But it has no place in long-term strat-
egy, probably because depression is a systemic
disease encompassing a constellation of symp-
toms that can only be cured once the depressive
disease is itself cured. Applying the results of sci-
entific research to clinical practice is a constant
challenge. A well-designed clinical trial may gen-
erate statistically significant data packaged in a
beautifully written paper. But the research set-
ting is often too abstracted from clinical reality.
It is thus no surprise that some costly studies
should have failed to impact clinical behavior. 
T he treatment of depression remains a mys-terious combination of science and art. Itis a science insofar as we know plenty about
the neurobiology of depression in terms of genet-
ic predisposition, neuroimaging changes, and
the biochemical and neuroprotective effects of
antidepressants. But it is an art in that we don’t
really know which therapeutic strategy will work
for which individual. Patients’ prioritization of
their depressive symptoms varies with age, gender,
occupation, and other sociodemographic vari-
ables. The elderly may emphasize the “meaning-
less of life,” while younger adults identify fatigue
or loss of energy as their primary concern. Cul-
ture is also important. In Asian societies, somatic
symptoms such as headache and poor appetite
are perceived as particularly distressing. They
occupy much the same position as anhedonia 
or depressed mood for Western patients. An in-
teresting study in white and Chinese elderly
showed that Chinese elderly had a more positive
attitude toward weight gain than their white
counterparts. In Chinese society, weight gain in
the elderly is perceived as “fa-foo” (literally, gain-
ing happiness, ie, a marker of wealth and a happy
family). Such people may be fat, but they are
“happy fat.” Generally speaking, anxiety and sleep
disturbance are the most distressing symptoms
of depression across all groups and they need to
be prioritized in the treatment strategy. However,
wise clinicians will always ask their patients
which symptom matters to them most. Patients
usually list several. The doctor can then work
with the patient to identify which comes first. The
order of symptom improvement is not only a
relevant clinical factor, but also a window onto
neural recovery by a depressed brain. No current-
ly available antidepressant offers rapid relief for
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be targeted with benzodiazepines and/or anti-
psychotics.
 Anxiety is common in depressive episodes and
contributes to the suicidal phenotype. Panic dis-
order in particular increases the risk of suicidal
behavior.1,2 Depending on acuteness and severity,
benzodiazepines and antidepressants are indi-
cated in combination with psychotherapy.
 Rapid relief of sustained insomnia stress en-
hances mood and provides resources for recovery.
Standard options are sedating antidepressants, eg,
amitriptyline or mirtazapine, or antipsychotics
and short-term benzodiazepines.
Outside the well-recognized influence of demog-
raphy, disease history, and somatic/psychiatric
comorbidity, antidepressant response has not been
clearly shown to differ with psychopathological
symptom profile. However, evidence suggests that
tricyclic antidepressants are more potent than
selective serotonin reuptake inhibitors (SSRIs) in
severely depressed inpatients.3 Indirect meta-anal-
ysis showed the dual-action serotonin-norepi-
nephrine reuptake inhibitor venlafaxine, intro-
duced in 1993, to be more effective than the SSRI
fluoxetine.4 Monoamine oxidase inhibitors may
be preferable for atypical features, eg, mood re-
activity, overeating and hypersomnia.5 Electro-
convulsive therapy is an option in life-threatening
situations or when otherwise appropriate drugs
are contraindicated. Depressive symptoms do not
respond to treatment at the same rate or to the
same degree. With some drugs, eg, the SSRI ser-
traline,6 this can be explained by individual phar-
macodynamics. Whether the order of symptom
improvement is relevant to episode outcome is
currently unknown. Recent review suggests that
residual symptoms (eg, subthreshold depressive
symptoms, cognitive impairment, and sexual dys-
function) influence long-term outcome: they in-
crease the risk of relapse, impede the return to
psychosocial and occupational functioning, favor
chronification, and increase suicide risk.7 As such,
they are major targets of long-term treatment
in depressive disorders. Thus, symptoms that are
life-threatening to the patient and/or others must
be the primary target of depressive episode treat-
ment, bearing in mind that not all symptoms
respond at the same rate or to the same degree.
Residual symptoms are common and must not
be overlooked in long-term treatment.8 
M ajor depressive episode is defined as aperiod of at least 2 weeks of depressedmood with suicidal ideation and abnor-
malities of neurovegetative function (altered 
appetite, weight loss, sleep disturbance [early
awakening]), psychomotor activity (loss of energy
and interest, agitation, retardation), and cogni-
tion (feelings of worthlessness, hopelessness, and
inappropriate guilt). A frequent additional fea-
ture is diurnal variation (morning depression).
While emotional symptoms such as depressed
mood and loss of interest have traditionally been
viewed as the core symptoms, the prevalence
and importance of anxiety and physical symp-
toms such as pain and fatigue are attracting in-
creasing attention. Antidepressant treatment
should be considered for patients meeting diag-
nostic criteria for depressive episode (ICD-10) or
major depressive episode (DSM-IV). Treatment
choice depends on the concurrent symptom pro-
file, the disease and treatment history, and pa-
tient preference. It should always target the most
severe symptoms, ie, those that most endanger
the patient and/or others.
 Suicidality and extreme malnutrition/dehy-
dration are life-threatening conditions requiring
priority acute treatment. Suicidality, whether
passive (the feeling that life is no longer worth
living) or active (ideation, planning, or attempted
implementation), is generally an indication for
inpatient treatment, in an intensive care unit if
acute. Fast-acting benzodiazepines are indicated.
Antidepressants that increase activation should
be used with caution and the response closely
monitored. Hospitalization is mandatory for ex-
treme malnutrition/dehydration since force-feed-
ing may be needed.
 Psychotic features, particularly delusions of
guilt and nihilistic thinking, are a major threat to
the patient and others. As such, they require im-
mediate targeting, usually with antipsychotics
(including benzodiazepines in the acute state) in
an inpatient setting.
 Anhedonia, a core feature of depression, is a
mandatory treatment target since the prolonged
inability to experience pleasure substantially in-
creases suicide risk. It requires antidepressants
and/or psychotherapy on an inpatient or outpa-
tient basis, depending on severity.
 Severe agitation stresses the patient and must
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changes,4 and the Mini International Neuropsy-
chiatric Interview. A major obstacle when assess-
ing the efficacy of antidepressants against their
primary targets is the remarkably high placebo
response rate in clinical trials. This has been as-
cribed to the intrinsic therapeutic effect of the
intensive monitoring involved.5 Placebo response
is inversely related to depression severity, being
more marked in the case of noncore symptoms
or milder, nonmelancholic disease. Although no
consistent difference has been found between
melancholic and nonmelancholic patients, most
studies record that only 20% to 30% of melan-
cholic patients respond to placebo. Low mood re-
activity is closely related to other core symptoms
in melancholia, and may thus be regarded as the
primary treatment target. In some studies, tri-
cyclic antidepressants are more effective in this
regard than selective serotonin reuptake inhib-
itors, but this is not a consistent finding.3 Total
remission should be the treatment target, as par-
tial response carries a high risk of relapse. 
D epression is a prevalent and devastatingdisorder with a complex etiology involvinga variety of neurobiological and socio-
economic factors.1 It is also multifaceted in its
phenomenology, manifested in shifting constella-
tions of symptoms and severities. High recurrence
rates and comorbid anxiety often impair function-
al capacity and quality of life. Melancholia has
been recognized since the fourth century BC. Its
key symptoms were long regarded as the core of
clinical depression, although they have recently
been portrayed as aligned more closely with bipo-
lar states.2 Melancholic symptoms have classi-
cally been the primary target for antidepressants
and electroconvulsive therapy. They show a sig-
nificantly lower placebo response, and may also
be less responsive to various forms of psychother-
apy.3 They have been widely tested using instru-
ments such as the Beck Depression Inventory,
via such items as sadness, past failure, loss of
pleasure, guilty feelings, punishment feelings, loss
of interest, irritability, and sleep and appetite
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or most important symptoms of depression. Few
studies have addressed the effects of drugs on
individual depressive symptoms, since the vast
majority of clinical trials have used total rating
scale scores as outcome variables. Analysis of the
outcome of each and every item on a depression
rating scale in a single trial would be subject to
statistical limitations associated with the issue
of multiple comparisons. Even when symptoms
are clustered, comparisons are still too many for
meaningful statistical analysis. Received wisdom
holds that antidepressants only begin to act after
2 or more weeks, with the corollary that any ear-
lier response is evidence of placebo rather than
pharmacological effect.4 Recent contrary data,
however, suggest that improvement in major de-
pression may occur much earlier, by the end of
the first week.5 This paradigm shift may encour-
age more studies on the sequential improvement
of depressive symptoms in clinical trials. The
therapeutic effects of antidepressants have been
differentiated from those of placebo on the basis
of the pattern of response over time rather than
of individual symptom response.4 An exception is
the depressive subtype melancholia, where symp-
toms such as lack of reactivity, morning depres-
M ajor depression, defined accordingto Diagnostic and Statistical Manual of Mental Disorders Fourth Revision
(DSM-IV) criteria, comprises at least five of the
following nine symptoms: depressed mood; loss
of interest or pleasure; weight loss; insomnia or
hypersomnia; psychomotor agitation or retarda-
tion; fatigue; feelings of worthlessness or guilt;
difficulty to concentrate; and suicidal ideation.1
These symptoms have been deemed most specific
of the disorder and hence most useful for making
valid and reliable diagnoses. Patients diagnosed
with depression, however, have many other symp-
toms, in particular anxiety. This explains why
scales designed to rate treatment response, eg, the
Hamilton Rating Scale for Depression (HAMD),
contain anxiety-related items. To aid differential
diagnosis between depressive subtypes and anxi-
ety disorders, studies have attempted to identify
the core signs and symptoms of depression, eg,
Parker’s work on motor retardation2 or the devel-
opment of the Newcastle Scales.3 However, with-
out hard biological markers to validate symptom
profiles derived from clinical studies, it is difficult
to establish borders between depressive, anxiety
and bipolar disorders, or even to identify the true
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son why bupropion is less prescribed than other
second-generation antidepressants appears to be
its lack of anxiolytic effect.12 Insomnia often fails
to respond to antidepressants in clinical trials
and may even worsen.13 Cotreatments targeted at
insomnia have therefore been proposed to aug-
ment response, remission, and adherence.14 Novel
antidepressants such as agomelatine, which target
underlying biorhythm disruption, are more effec-
tive in sleep disturbance and may have an impor-
tant impact in the clinical management of major
depression.15 Antidepressants that differ in their
mechanisms of action may differ in the degree and
timing of their effects on individual symptoms.
Thus, the first symptoms to respond to the nor-
epinephrine reuptake inhibitor desipramine and
the selective serotonin reuptake inhibitor paroxe-
tine were psychomotor retardation and anxiety,
respectively, while placebo showed no pattern of
improvement in association with subsequent re-
mission and response in a clinical trial.16 In sum-
mary, limited evidence suggests that the symptom
to be prioritized in the treatment of major depres-
sion is not one conventionally classified as depres-
sive, but anxiety, in particular psychic anxiety. 
sion, terminal insomnia, marked retardation,
significant weight loss, and excessive guilt have
been shown to predict poor placebo response.6 In
theory there is an urgent practical need to pri-
oritize certain symptoms, in particular suicidal
ideation. However, there is disputed evidence that
antidepressants are associated with treatment-
emergent suicidal ideation and suicide-related
behavior, although not with completed suicide, in
children, adolescents and adults; on this basis,
current antidepressants may be ineffective for se-
curing rapid control of suicidal ideation or suicide
attempts.7 A good case for prioritized treatment
could also be made for any symptom whose ini-
tial improvement is associated with better sub-
sequent outcome. The few studies of sequential
improvement in depressive symptoms suggest that
early decreases in anxiety—HAMD 17 anxiety-
somatization factor and psychic anxiety—are as-
sociated with subsequently higher responder and
remitter rates.8-10 Interestingly, these findings are
consistent with current practice in that the effect
of antidepressants on anxiety symptoms is the
main feature that doctors consider when choos-
ing one drug over another.11 Thus the main rea-
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development of depression as shown in several
epidemiological studies2 and borne out in clinical
experience. Antidepressants that relieve certain
symptoms without correcting sleep disturbance
will not achieve a significant response and will
incur a high rate of relapse. Patients feel better
if their sleep disturbance improves early during
treatment. They are otherwise likely to feel worse.
The risk that selective serotonin reuptake inhib-
itors may initially worsen sleep should be coun-
teracted by the addition of hypnotics. The ideal
antidepressant is a drug that rapidly improves
sleep and resets the circadian system. Sleep dis-
turbance should thus be the primary target in
treating depression. This recommendation may
appear to conflict with the rapidly positive effect
that sleep deprivation may have in melancholia.
However, sleep deprivation works by resetting the
disrupted circadian system. Other methods that
act on the circadian pacemaker can be equally
effective. In order to improve sleep as a basis for
mood reversal, there are thus sound scientific as
well as clinical grounds for prioritizing circadian
rhythm in the treatment of depression. 
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I nsomnia is both a symptom and cause of de-pression. It may even be the worst symptom:to lie awake unable to rest while a prey to
pessimistic thoughts is torment. Insomnia is a
proven marker for increased suicidality. We re-
cently showed a correlation between sleep distur-
bance, in particular nightmares, and suicidality
and suicide attempts.1 Sleep disturbance in de-
pression—sleep-onset insomnia, frequent noctur-
nal awakening, and early morning awakening—
reflects underlying circadian dysregulation,
mediated by the suprachiasmatic pacemaker. Dys-
functional circadian input may also influence
monoaminergic activity, lowering serotonin ac-
tivity and melatonin levels, with effects on time-
keeping and hence sleep. Stress has a major role
in the development of depression. Some degree
of stress is tolerable, but overload is harmful.
Disturbed sleep is the best clinical sign of exces-
sive stress. Stress can be tolerated as long as sleep
function is normal. But insomnia is evidence of
an overactive hypothalamo-pituitary-adrenal axis.
The regulatory peptide corticotropin-releasing
factor not only influences the release of adreno-
corticotropic hormone, but also the limbic sys-
tem, inhibiting delta sleep. This dysregulation
may also feed back onto the circadian pacemaker.
Disruptions in the biological clock mechanism
may be both a cause and a consequence of de-
pression. Insomnia is itself a risk factor for the
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that these symptoms, in some unknown way, play
a central role in the pathophysiology of the disor-
der. They must therefore be considered as treat-
ment priorities. Clinical experience also teaches
us that cognitive symptoms are important for
informing treatment strategy in depression. They
respond quite independently from other symptom
clusters. When patients improve in their mood
and associated physical symptoms, they often
retain the same cognitive disturbance as in the
acute phase of the disorder. Clinical experience
teaches us that treating cognitive symptoms first
has practically no effect on relieving depression,
except in its milder forms. The implication is that
we must first treat the core symptoms, at least in
severe depression, if we are to achieve any glob-
al improvement that allows intervention against
cognitive symptoms. The conclusion informed
by clinical experience is that the core symptoms
of depressed mood and anhedonia must be treat-
ed first, at least in severe depression, and that
cognitive symptoms should be targeted in the
second phase of treatment. Clinical experience
has shown that improvement in depressive mood
is a precondition for obtaining significant bene-
fit from cognitive remediation therapy. 
W hy should we need to prioritize targetsymptoms in the treatment of depres-sion? The question presupposes that
some symptoms are more life-threatening or sig-
nificant than others. Our first task is therefore to
hierarchize symptoms along these lines. Depres-
sion is commonly viewed as comprising core
symptoms (depressed mood and anhedonia) asso-
ciated with three (emotional, physical, and cog-
nitive) symptom clusters. However, this view is
unsupported by any pathophysiological mecha-
nism or mechanisms common to all forms of
depression. Until such mechanisms are identified,
we have no option but to base our definition of
depression, and our resulting treatment options,
on the phenomenology of the disorder. If we now
analyze the structure of these phenomenological
symptom clusters, can we hierarchize certain
symptoms in terms of risk or their potential im-
pact on other symptoms, such that successful
treatment of one symptom could encompass a
spectrum of others? In the absence of hard phys-
ical data, we can only base our answer on clini-
cal experience. What that experience teaches us
is that if we first treat the core symptoms, we
achieve global clinical improvement. This suggests
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sion were the first to improve.5 As no biological
markers for antidepressant treatment have been
found and as current practice relies on rating
scales, assessment of a patient’s treatment has to
be based on improvement in the core symptoms,
especially during the early treatment period.1,2,5
Clinically, the degree of symptom response is
more relevant than its order, although there does
appear to be a characteristic order of symptom
response to antidepressants. Residual symptoms
are less sensitive to antidepressants and may be
more clinically relevant in that they heighten
the risk of relapse.6 Our (unpublished) finding in
nonpsychotic major depressive disorder is that
the negative self-concept factor in the BDI (items
such as feeling of guilt, sense of punishment,
self-hate, and self-accusation) is relatively less
sensitive to change than observer ratings. This
factor may therefore be clinically relevant in
treating depression.
Is the placebo effect more important for some
noncore symptoms?
Recent neurobiological studies suggest that place-
bo effects are not as simple as previously thought
and that they may be clinically relevant by en-
hancing the effect of specific treatments.7,8 In
the hierarchy of classes of personal illness model
proposed in 1975 by Foulds and Bedford,9 depres-
sion occupies a lower hierarchical class. Endoge-
nous depression, on the other hand, especially
melancholia and psychotic depression, appears
more biologically determined,10 and does not oc-
cupy a lower hierarchical class. Studies from the
1970s suggest that the frequency of placebo effects
increases from anxiety disorder, through depres-
sive disorder, to schizophrenia. If we assume that
core symptoms are the final common pathway in
the pathogenesis of depression and that placebo
effects are salient solutions to given stimuli in
an individual,7,8 the noncore symptoms that could
be classified in the lowest hierarchical class9 may
be more likely to respond via a placebo effect. 
I would nominate as the priority treatmenttarget one of the so-called core symptoms,such as depressed mood, lack of interest,
lack of energy, guilt, psychic anxiety, or somatic
anxiety.1,2 This is because improvement in core
symptoms tends to benefit other symptoms and
eventually lead to full remission. However, it is
difficult to identify the core symptom(s) in an
individual patient because depression is hetero-
geneous in its pathogenesis. Since psychiatric
symptoms can be clinically differentiated at mul-
tiple levels, phenomenological similarity does not
reflect similarity of origin or structure.3 A further
complication is that the symptoms that appear
as priorities for the patient may not be those that
require priority treatment: our (unpublished)
observations indicate that the Beck Depression
Inventory (BDI) is less sensitive than clinician
rating at identifying responders and remitters,
especially in the early treatment period. Thus, at
present, clinicians are obliged to choose a core
symptom as their priority treatment target be-
cause antidepressants have shown no specific
differences in their mechanism of action on tar-
get symptoms.2
Is the order of symptom improvement a relevant
clinical factor?
The order of symptom response to antidepres-
sants appears to depend on the drug receptor
profile. For example, duloxetine, a serotonin-nor-
epinephrine reuptake inhibitor, improved de-
pressed mood, guilt, suicidal ideation, work/ac-
tivity, and anxiety in the first week, motor
retardation in the second week, motor retardation
and hypochondriasis in the third week, and gen-
eral somatic symptoms, insomnia, and insight
after the fifth week.4 With desipramine, a tricyclic
antidepressant that inhibits the reuptake of nor-
epinephrine, early response was shown by motor
retardation and depressed mood, while with the
selective serotonin reuptake inhibitor paroxetine,
anxiety, depressed mood, and distressed expres-
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first or recurrent depressive episode.3 Current
pharmacological classes of antidepressants allow
clinicians to choose the most appropriate agent
in light of specific symptom patterns. Certain
drugs show symptom specificity. Serotonin nor-
epinephrine reuptake inhibitors (SNRIs), for ex-
ample, are most effective in cognitive disturbance
and/or somatic complaints such as pain.4 Mir-
tazapine and trazodone may be particularly
useful in sleep disturbance,5 along with melaton-
ergic agents such as agomelatine.6 The holy grail
of pharmacotherapy is to develop rapid-onset
agents that accelerate symptom response and
remission. Recent examples include escitalopram,
a selective serotonin reuptake inhibitor (SSRI),
and the SNRIs venlafaxine and duloxetine. How-
ever, rapid onset of effect is not the only factor
to consider in a treatment plan, even in severe
disease. Tolerability is a critical consideration
when efficacy depends on treatment compliance.
Therapeutic strategy must therefore be based 
on a combination of disease factors (symptom
severity, profile, and duration, and pattern of 
recurrence 7) and pharmacotherapeutic factors
(efficacy, tolerability, and time to effect). In pri-
oritizing treatment targets, consideration should
be given to the most urgent symptoms, especially
if somatic, suicidal, and/or psychotic, followed
by the patient’s own symptom hierarchy. But
the restoration of the fundamental biological
rhythms governing sleep, appetite, and other
functions must never be neglected. Biorhythm
normalization is essential for breaking the vicious
cycle of dysregulated affective brain circuits and
dysfunctional hypothalamus that can underlie
the core biological symptoms of depression.
Dysfunctional biorhythms maintain cortical and
subcortical circuit imbalance and vice-versa.
Drugs designed to normalize biorhythm disrup-
tion may be the most promising additions to the
pharmaceutical armamentarium against major
depression. 
P rioritizing symptoms in order to optimizetreatment strategy is a crucial and com-plex issue in managing major depression.
Depressed patients often overemphasize specific
symptoms (eg, cognitive disturbance, loss of 
interest, sleep difficulties). This may be useful in
establishing the diagnosis, but it can be mislead-
ing in informing treatment choice. Patients may
stress certain persistent symptoms (eg, insom-
nia, somatic symptoms) at the expense of others
that appear less severe, but are more meaningful
in terms of drug response. In addition, there are
specific populations, such as the elderly, with
their own clinical patterns, which tend to be more
severe and to carry a poorer prognosis than in
nonelderly adult depressives:1 elderly depres-
sives have more somatization, hypochondriasis,
anxiety/retardation, and delusionality, but less
guilt, loss of libido, and family history of depres-
sion, as well as a less predictable therapeutic
response; despite much lower medication doses,
side effects are also more troublesome in this
age group.2 Given the symptom heterogeneity, it
is mandatory to use standardized rating scales,
such as the Hamilton Depression Rating Scale
and Montgomery-Asberg Depression Rating Scale,
for qualitative and quantitative assessment and
for optimizing intervention. In choosing an initial
treatment modality, the first consideration is
the setting: the choice between hospitalization
and outpatient care depends on suicidal ideation
and symptom severity, in particular the presence
or absence of psychotic features. The second con-
sideration is the choice between pharmacology
and electroconvulsive therapy, and if pharmacol-
ogy, the choice of agent. Life-threatening situa-
tions must be addressed as rapidly as possible for
the safety of patients and those around them. Less
urgently, in order to minimize the development
of antidepressant resistance, it is important to
consider the duration of certain symptoms and
of untreated illness in patients experiencing a
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